• Explore /
  • Poster
  • / FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (GDC-0068) in combination with paclitaxel as neoadjuvant treatment for early stage triple-negative breast cancer.

FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (GDC-0068) in combination with paclitaxel as neoadjuvant treatment for early stage triple-negative breast cancer.

Abstract Poster

Authors

null

Steven J. Isakoff

Massachusetts General Hospital Cancer Center, Boston, MA

Steven J. Isakoff , Cristina Saura , Isabel Calvo , Miguel J. Gil Gil , Debra A. Patt , Serafin Morales Murillo , Jay C. Andersen , EVA Ciruelos , Julie Gottlieb Fisher , Jose Passos-Coelho , Lorena de La Pena , Amy V. Kapp , Steven Gendreau , Wai Y. Chan , Stina Mui Singel , Daniel J. Maslyar , Jose Baselga , Mafalda Oliveira

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy

Track

Breast Cancer

Sub Track

Triple-Negative Breast Cancer

Clinical Trial Registration Number

NCT02301988

Citation

J Clin Oncol 34, 2016 (suppl; abstr TPS1105)

DOI

10.1200/JCO.2016.34.15_suppl.TPS1105

Abstract #

TPS1105

Poster Bd #

205b

Abstract Disclosures

Similar Posters

First Author: Mafalda Oliveira

First Author: Liulu Zhang

First Author: Rebecca Alexandra Dent

First Author: Virginia G. Kaklamani